Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06993610 · ClinicalTrials.gov registry record · Phase 2
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
A Phase 2 study of Hidradenitis Suppurativa (HS), sponsored by Zura Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 225
- Enrollment target
- 20
- Study locations
NCT06993610 is a Phase 2 study of Hidradenitis Suppurativa (HS) that is actively recruiting participants, run by Zura Bio. The registered enrollment target is 225 participants, above the 162-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (39% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06993610, a Phase 2 study of Hidradenitis Suppurativa (HS), is actively recruiting participants, sponsored by Zura Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 225 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Tibulizumab Dose A
- BIOLOGICAL Tibulizumab Dose B
Study Locations (20)
California
- First OC Dermatology Research, Inc. - Irvine
- Wallace Medical Group, Inc. - Los Angeles
- Northridge Clinical Trials - Northridge
- NorCal Clinical Research - Rocklin
Indiana
- Indiana University School of Medicine - Indianapolis
- The Indiana Clinical Trials Center - Plainfield
Kentucky
- Equity Medical LLC (Kentucky) - Bowling Green
- DS Research of Kentucky, LLC - Louisville
Louisiana
- DelRicht LLC - Baton Rouge
- Clinical Trials Management, LLC - Metairie
New York
- Equity Medical - New York
- OptiSkin Medical - New York
Ohio
- Optima Research - Boardman
- ClinOhio Research Services - Columbus
Arizona
- Medical Dermatology Specialists (Phoenix) - Phoenix
Florida
- Florida Academic Dermatology Center - Coral Gables
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2025-05-16 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06993610
The ClinicalTrials.gov registry entry for NCT06993610 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 162-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (39% higher). The listed sponsor is Zura Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06993610 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Indiana, Kentucky.
Frequently Asked Questions
What is clinical trial NCT06993610 about?
NCT06993610 is a clinical study titled "Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense". The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Peri...
What is the current status of trial NCT06993610?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2025-05-16. Estimated completion is 2027-04.
What conditions does trial NCT06993610 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).
What interventions are being tested in trial NCT06993610?
The interventions under investigation include: Placebo (OTHER), Tibulizumab Dose A (BIOLOGICAL), Tibulizumab Dose B (BIOLOGICAL).
Who is sponsoring clinical trial NCT06993610?
This trial is sponsored by Zura Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06993610 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa (HS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
RECRUITING · Phase 2
-
The Safety and Efficacy of Roflumilast Foam in HS
RECRUITING · Phase 2
-
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
Hidradenitis Suppurativa Wound Care
COMPLETED · Phase 2
-
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.